Ronald W. Penczek - 01 Mar 2024 Form 4 Insider Report for Elevance Health, Inc. (ELV)

Role: CAO & Controller
Signature: /s/ Kathleen S. Kiefer, Attorney in fact
Issuer symbol: ELV
Transactions as of: 01 Mar 2024
Net transactions value: -$191,159
Form type: 4
Filing time: 05 Mar 2024, 16:32:38 UTC
Previous filing: 01 Dec 2023
Next filing: 08 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELV	Common Stock	Tax liability	$191,159	-383	-21%	$499.11	1,408	01 Mar 2024	Direct	F1
transaction	ELV	Common Stock	Award	$0	+226	+16%	$0.000000	1,634	01 Mar 2024	Direct	F2
transaction	ELV	Common Stock	Award	$0	+1,046	+64%	$0.000000	2,680	01 Mar 2024	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELV	Employee Stock Option (Right to Buy)	Award	$0	+867		$0.000000	867	01 Mar 2024	Common Stock	867	$499.11	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.
F2	Represents restricted share units. Restrictions lapse as follows: 75 shares each on 3/1/2025 and 3/1/2026 and 76 shares on 3/1/2027.
F3	Represents performance based restricted share units. Restrictions lapse on 3/1/2024.
F4	Balance includes 4.20 shares acquired on December 21, 2023 through a dividend reinvestment plan.
F5	The option represents a right to purchase a total of 867 shares, and is exercisable in three annual installments of 289 shares each, beginning on 3/1/2025, which is the one-year anniversary of the option grant date.